Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection

Citations Over TimeTop 12% of 2018 papers

Abstract

Tenofovir alafenamide (TAF) is indicated for adult patients with chronic hepatitis B virus (HBV) infection with compensated liver disease at an oral dose of 25 mg/day. TAF is a more stable prodrug in the plasma than tenofovir disoproxil fumarate (TDF), leading to decreased plasma exposure of tenofovir. Decreased exposure is thought to reduce the risk of long-term TDF toxicities, such as nephrotoxicity and decreased bone mineral density (BMD). TAF, a nucleotide reverse transcriptase inhibitor, has the same mechanism of action as TDF. The results of phase III primary trials and extensions showed that TAF is noninferior to TDF at suppressing the HBV viral load in treatment-naive and treatment-experienced HBeAg-negative and HBeAg-positive patients at 48 weeks, 96 weeks, and 144 weeks of therapy. The most commonly reported adverse events were headache, abdominal pain, fatigue, cough, nausea, and back pain. At all evaluated time points (out to 144 wks of treatment), patients who received TAF had less risk of nephrotoxicity and less of a decline in BMD than the patients who received TDF. TAF appears to be safe in patients with a creatinine clearance (Cl_cr ) above 15 ml/min; however, TAF is not currently recommended in patients with an estimated Cl_cr below this threshold. TAF is safe in patients with mild hepatic impairment but is not currently recommended in patients with moderate or severe hepatic impairment (Child-Pugh class B or C).

Related Papers

• → 57 TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR THE TREATMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B: WEEK 72 TDF DATA AND WEEK 24 ADEFOVIR DIPIVOXIL SWITCH DATA (STUDY 102)(2008)36 cited
• → A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results(2020)4 cited
• → FRI-165-No detectable resistance to tenofovir in patients with Adefovir- and Entecavir-resistant chronic hepatitis B after 240 weeks of treatment with tenofovir disoproxil fumarate monotherapy(2019)1 cited
• → F-14 Hypophosphatemia in Caucasian HBV patients treated with tenofovir is influenced by previous adefovir treatement(2013)
• → 520 RESPONSE TO TENOFOVIR TREATMENT OF TREATMENT-NAIVE VS ADEFOVIR-RESISTANT VS SUBOPTIMAL RESPONDER PATIENTS WITH CHRONIC HEPATITIS B(2012)